
Health exclusion affects more than three in five people globally
- Phase two of Economist Impact’s Health Inclusivity Index, supported by Haleon, measures experience of health inclusion across 42,000 people in 40 countries
- Health inclusivity scores fall worldwide with addition of lived experience data, exposing glaring policy-practice gap in wealthy countries
- 66% of survey respondents experience barriers to health inclusion, with the most vulnerable worst affected
- Index reveals stark generational divide with Gen Z and Millennials experiencing greater barriers to access and higher levels of discrimination
LONDON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- More than three in five people worldwide experience health exclusion, with vulnerable and younger populations the worst affected, according to phase two of the global Health Inclusivity Index from Economist Impact, supported by consumer health company Haleon.
This year’s study – which measures the extent and experience of health inclusion across 40 countries and 42,000 people – revealed that 66% of those surveyed face at least one barrier in accessing healthcare services. Lack of available appointments; inconvenient hours; distance and cost of travel; and lack of trust in healthcare services were the most widely reported barriers. Alarmingly, the Index also revealed that one in five people worldwide (20%) lack access to mental health services in their community, while 17% lack access to sexual health services.
The study suggests that younger generations face particular issues, with almost half of Gen Z (45%) stating their quality of care has been compromised as a result of their age, health status, or other personal factors, compared with 19% of Baby Boomers. Almost a third of Gen Z (28%) and Millennials (32%) report that their pain or health conditions are not taken seriously by healthcare professionals. While almost a quarter of Gen Z (21%) and Millennials (22%) report they’ve been completely denied access to healthcare, compared with just 8% of Baby Boomers.
Besides appointment hours and availability, together with distance and cost to travel, Gen Z are the most likely to cite lack of trust in healthcare providers and fear of discrimination as major obstacles when seeking healthcare services. 44% of Gen Z also cited social media as a trusted source of health information and advice – the highest proportion amongst all generations surveyed.
The most vulnerable populations, namely people from marginalised groups and those with chronic health conditions, also report being denied access to healthcare (26%). Discrimination is a key barrier, with more than a quarter (27%) of those from marginalised groups and people with chronic health conditions experiencing this when interacting with healthcare providers.
Sarah McDonald, VP Sustainability and Social Impact, Haleon, said: “With the Index revealing high rates of health exclusion worldwide, more action is needed to overcome the barriers, particularly for vulnerable populations. These latest findings reveal a clear gap between policy and experience, as the inclusive health ambitions of many of the world’s wealthiest countries are out of step with the reality of their citizens. As we saw in phase one of the research, the Index demonstrates that empowering people and communities to take care of their health is key. A greater focus on community services, self-care and health literacy programmes can boost inclusion, bringing better everyday health within reach of more people.”
The first phase of the Index, launched in 2022, examined the presence, coverage and effectiveness of inclusive healthcare systems, policies and programmes. The research methodology for 2023’s phase two study has been enhanced to include an assessment of people’s experience of these inputs – by capturing insights from 42,000 people to understand their experiences of health inclusion or exclusion.
With the addition of this lived experience data, health inclusivity scores have deteriorated under phase two of the Index across 85% of the countries surveyed. For example, the UK’s score fell by 13%, falling from first to third place, behind Australia and Sweden. With all but one country scoring below 80 out of 100, it’s clear that governments and policymakers have a long way to go in tackling health exclusion.
The declining scores year-on-year expose a policy-practice gap between governments’ ambitions of delivering inclusive health policies and systems and people’s real-life experience of them. High income countries display the largest gaps, with an average 18-point difference between their scores on inclusive health policies and people’s real-life experience, with Germany showing the greatest discrepancy. This reveals that many of the world’s wealthiest nations are struggling to deliver inclusive health policies and systems effectively, with marginalised and vulnerable populations at greatest risk of exclusion.
Jonathan Birdwell, Global Head of Policy and Insights, Economist Impact, said: “Measuring a country’s ability to provide quality healthcare involves evaluating its policy but also its population’s ability to use their healthcare services. That’s why we are pleased to add lived-experience indicators to Economist Impact’s Health Inclusivity Index. The results of this phase of the Index show that high-income countries still have a lot of improvements to make if they are to effectively turn their policy into action.”
In common with last year’s findings, phase two of the Index concludes that empowering people and communities to have greater agency over their own health is a key driver of inclusion. Low-and-middle income countries outperform wealthier countries in this area due to their focus on community-based services, self-care and health literacy programmes. For example, 73% of people in low-and-middle income countries have been given advice or information on managing their health at home, compared with 65% for high-income countries.
Consequently, low-middle income countries display an average policy-practice gap of just 3-points and are more effective at ensuring inclusion for marginalised groups, those with chronic health conditions and Gen Z. The fact that countries with less developed infrastructure, lower spending and fewer resources are more effective in delivering population-level health inclusivity in practice is a rich source of learning for both high-and lower-income countries.
As a global leader in consumer health, Haleon will leverage this and other learnings from the Index to engage governments, policymakers and partners around the globe and work together to tackle the biggest barriers to health inclusivity.
Under phase two of the Health Inclusivity Index, Australia achieves the highest score, followed by Sweden, UK, USA, France, Israel, Canada, South Korea, Germany, Switzerland and Thailand. The full findings of the Index can be found here: https://impact.economist.com/projects/health-inclusivity-index
Media Contacts: | |
Haleon Media Contact: Gemma Thomas gemma.x.thomas@haleon.com +44 (0) 7721376006 | Economist Impact Media Contact: Holly Donahue hollydonahue@economist.com |
Notes to Editors:
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Haleon and Health Inclusivity
Haleon’s social impact goal is to empower millions of people a year to be more included in opportunities for better everyday health – with the company aiming to reach 50 million people a year by 2025. During 2022, we empowered more than 22.4 million people.
We have identified three key barriers to health inclusivity that Haleon is well placed to help address, which are:
• health literacy;
• healthcare accessibility; and
• bias & prejudice
Examples of Haleon’s efforts to break down barriers to health inclusivity include:
Health Literacy:
Our Caltrate calcium supplement brand in China has run several initiatives to raise awareness of the risks of osteoporosis and how to actively prevent and manage it. This includes working with Health Professionals to reach more consumers through online education, in-person outreach and bone density tests.
Healthcare Accessibility:
To help make our brands more accessible, we have collaborated with Microsoft on expanding the functionality of their Seeing AI app for Haleon products. Seeing AI is a free mobile app that scans the information on product labels and reads it out loud. Consumers can scan the barcode on UK and US Haleon products and hear crucial information such as name, ingredients, and usage instructions.
Bias and Prejudice:
The Advil Pain Equity Project is a long-term commitment to champion equitable and accessible pain relief in the United States, created by Advil and launched in partnership with Morehouse School of Medicine and BLKHLTH. The Advil Pain Equity Project's first campaign, Believe My Pain, is focused on illuminating the issue of pain inequity in Black communities.
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
About Economist Impact
Economist Impact combines the rigour of a think-tank with the creativity of a media brand to engage a globally influential audience. We believe that evidence-based insights can open debate, broaden perspectives and catalyse progress. The services offered by Economist Impact previously existed within The Economist Group as separate entities, including EIU Thought Leadership, EIU Public Policy, Economist Events, El Studios and SignalNoise. Our track record spans 75 years across 205 countries. Along with creative storytelling, events expertise, design-thinking solutions and market-leading media products, we produce framework design, benchmarking, economic and social impact analysis, forecasting and scenario modelling, Press Release making Economist Impact's offering unique in the marketplace. Visit www.economistimpact.com for more information.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a24060d5-eb9b-4fa1-8cbf-e5427cfaaa24
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation5.12.2023 07:00:00 CET | Press release
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2 Data will be shared with health authorities and presented at an upcoming medical meeting Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to pal
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury5.12.2023 04:41:56 CET | Press release
With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile. SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group. Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3. In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition
Nokia comments on AT&T vendor plans5.12.2023 03:30:00 CET | Press release
Nokia Corporation Stock Exchange Release 5 December 2023 at 4:30 EET Nokia comments on AT&T vendor plans Espoo, Finland – Nokia has a wide-ranging relationship with AT&T, supplying products and services across wireless, wireline and other network technologies, alongside similar relationships with other major North American network operators. Nokia is aware of AT&T’s plans to commit to an Open RAN deployment in collaboration with other vendors over the next five years. As a result, Nokia now expects revenue from AT&T in Mobile Networks will decrease over the next 2-3 years. AT&T accounted for 5-8% of Mobile Networks net sales year-to-date in 2023. The already announced action Nokia is taking to reduce its cost base is expected to partially mitigate the impact of AT&T’s decision. Nokia expects Mobile Networks to remain profitable over the coming years but this decision would delay the timeline of achieving double digit operating margin by up to 2 years. Nokia has invested heavily in the
Canadian Government Awards New Funding to General Fusion5.12.2023 02:00:00 CET | Press release
RICHMOND, Canada, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Today, General Fusion announced that Canada’s Strategic Innovation Fund (SIF) has awarded CA$5 million to support research and development to advance the company’s Magnetized Target Fusion (MTF) demonstration at its Richmond headquarters. Called LM26, this ground-breaking machine will progress major technical milestones required to commercialize zero-carbon fusion power by the early to mid-2030s. The funds are an addition to the existing contribution agreement with SIF, to support the development of General Fusion’s transformational technology. Fusion energy is the ultimate clean energy solution. It is what powers the sun and stars. It’s the process by which two light nuclei merge to form a heavier one, emitting a massive amount of energy. By 2100, the production and export of the Canadian industry’s fusion energy technology could provide up to $1.26 trillion in economic benefits to Canada. Additionally, fusion could completely offset
LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination4.12.2023 23:30:00 CET | Press release
QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek Aberle and chaired by former Qualcomm Vice Chairman Steve Altman, today announced that on December 4, 2023 the U.S. Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4, as amended, filed by LeddarTech Holdings Inc. (“Newco”) in connection with the previously announced proposed business combination (the “Business Combination”). The filing can be viewed in its entirety on the SEC’s website at www.sec.gov. Prospector also commenced mailing the definitive proxy statement/prospectus on December 4, 2023, which was included in the Reg